Important Considerations When Diagnosing NETs
Andrew E. Hendifar, MD, explains how neuroendocrine tumors are classified and categorized and how the diagnostic criteria help experts formulate treatment plans for patients.
Related Articles
Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer
Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.
NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma
An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.
IBI363 Receives FDA Fast Track Designation for Advanced/Metastatic Melanoma
The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma
The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.
Heme & Onc Fellow Board Review Tips 2024
Drs Armstrong and Tawagi discuss high-yield oncology and hematology topics to focus on when studying for the 2024 oncology board exams.
Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape
A panel of experts offer future perspectives in HR+ breast cancer.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Dr. Jasmine Zain: Challenges in T-Cell Lymphoma Treatment
Jasmine Zain, MD, director of the T-cell Lymphoma Program, professor of hematology and hematopoietic stem cell transplantation, of City of Hope National Medical Center, discusses…
Analysis Further Shows Perioperative Pembrolizumab Efficacy in Early-Stage NSCLC
Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.